Literature DB >> 12717241

Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice.

Major K Lee1, Xiaolun Huang, Beth P Jarrett, Daniel J Moore, Niraj M Desai, Moh Moh Lian, Joseph W Markmann, Shaoping Deng, Adam Frank, Andrew Singer, Ergun Velidedeoglu, Andrew J Caton, And James F Markmann.   

Abstract

BACKGROUND: Examination of the in vivo activation and function of CD4+ T cells in response to allografts may advance our understanding of the rejection process. We analyzed the capacity of transgenic class II-restricted CD4 T cells to reject skin, cardiac, and islet transplants.
METHODS: TS1 mice possess a high frequency of CD4+ T cells specific for the immunodominant epitope of the viral hemagglutinin (HA) protein. We analyzed the kinetics of rejection of skin, heart, and islet grafts by naïve and sensitized TS1 mice and by adoptively transferred TS1 lymphocytes.
RESULTS: Rejection of heart transplants was more rapid than skin grafts (mean survival time, 12.9 vs. 26.6 days), and islet grafts survived indefinitely in TS1 mice. These findings may be partly attributable to the supranormal frequency of HA-reactive cells in TS1 mice. In support of this, we found that adoptive transfer of 5 x 10(5) TS1 lymphocytes to Balb/c hosts effected consistent rejection of HA-bearing skin transplants, whereas a significantly greater number (3 x 10(6)) was required for heart transplant rejection. The in vivo proliferative response of HA-specific T cells to heart and skin was found to be robust and predominantly localized to the draining lymph nodes.
CONCLUSION: We developed a model of allograft rejection in which the responding T cells and relevant graft antigen are specifically defined. Adoptive transfer of carboxy-fluorescein succinimidyl ester-labeled transgenic T cells allowed us to visualize a robust proliferative response in vivo to heart and skin allografts, which in both cases was localized to regional lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717241     DOI: 10.1097/01.TP.0000064296.65628.6C

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Blockade of GITR-GITRL interaction maintains Treg function to prolong allograft survival.

Authors:  James I Kim; Samsher B Sonawane; Major K Lee; Seoung-Hoon Lee; Patrick E Duff; Daniel J Moore; Matthew R O'Connor; Moh-Moh Lian; Shaoping Deng; Yongwon Choi; Heidi Yeh; Andrew J Caton; James F Markmann
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

2.  Generation of adaptive regulatory T cells by alloantigen is required for some but not all transplant tolerance protocols.

Authors:  James I Kim; Matthew R O'connor; Patrick E Duff; Gaoping Zhao; Kang Mi Lee; Philip Eliades; Shaoping Deng; Heidi Yeh; Andrew J Caton; James F Markmann
Journal:  Transplantation       Date:  2011-04-15       Impact factor: 4.939

3.  Regulatory T-cell counter-regulation by innate immunity is a barrier to transplantation tolerance.

Authors:  J I Kim; M K Lee; D J Moore; S B Sonawane; P E Duff; M R O'Connor; H Yeh; M M Lian; S Deng; A J Caton; J F Markmann
Journal:  Am J Transplant       Date:  2009-10-21       Impact factor: 8.086

4.  B-cell depletion improves islet allograft survival with anti-CD45RB.

Authors:  Kang Mi Lee; Heidi Yeh; Gaoping Zhao; Lingling Wei; Matthew O'Connor; Ryan T Stott; Julie Soohoo; Kyri Dunussi; Paolo Fiorina; Shaoping Deng; James F Markmann; James I Kim
Journal:  Cell Transplant       Date:  2012-11-27       Impact factor: 4.064

5.  Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation.

Authors:  Go Itakura; Yoshiomi Kobayashi; Soraya Nishimura; Hiroki Iwai; Morito Takano; Akio Iwanami; Yoshiaki Toyama; Hideyuki Okano; Masaya Nakamura
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

6.  A direct comparison of rejection by CD8 and CD4 T cells in a transgenic model of allotransplantation.

Authors:  Paige M Porrett; Major K Lee; Moh Moh Lian; Jing Wang; Andrew J Caton; Shaoping Deng; James F Markmann; Daniel J Moore
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.